Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers worldwide and continues to increase in incidence. Advanced CSCC can be particularly aggressive and has historically had limited treatment options. Come learn about the mechanism of action, clinical efficacy and safety data, patient eligibility, and dosage and administration of an FDA approved treatment option for appropriate patients suffering from advanced CSCC.
Company: Sanofi Genzyme
Contact: Zack McCormack
The asset you are trying to access is locked. Please enter your access key to unlock.